TIDMAGL
Angle PLC
09 July 2021
For immediate release 09 July 2021
ANGLE plc ("the Company")
PARSORTIX USED TO SUCCESSFULLY HARVEST CANCER CELLS FOR ANALYSIS
FROM THE BLOOD OF PATIENTS WITH BRAIN METASTASIS
Parsortix successful in overcoming challenges associated with
isolating CTCs from brain metastasis patients in three different
cancer types
Analysis of CTCs may enable more personalised care for cancer
patients with brain metastasis where traditional tissue biopsy is
not possible
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that University Medical Centre
Hamburg-Eppendorf has published results of new work undertaken in
patients with brain metastasis demonstrating use of ANGLE's
Parsortix(R) system in the isolation of circulating tumour cells
(CTCs). In addition, the research investigated the role of two
proteins, CD74 and CD44, in the development of brain
metastasis.
Liquid biopsy from peripheral blood is a particularly attractive
solution in brain cancer because of the difficulty, medical
complications and cost associated with taking a tissue biopsy from
the brain. The characterisation of metastatic tumour cells can be
crucial in helping to inform personalised treatment decisions, but,
because of the serious risks involved, most patients with brain
metastasis will never undergo a tissue biopsy unless undergoing
surgical tumour resection.
Historically, detection of CTCs from peripheral blood in brain
metastasis has been hampered by the blood-brain-barrier which
results in fewer CTCs in peripheral blood compared to other
metastatic sites and, because these CTCs have a more mesenchymal
state, they are poorly detected using antibody-based systems. In
this study, 44 patients with primary breast cancer, non-small cell
lung cancer (NSCLC) and melanoma with subsequent brain metastases
were screened for CTCs using the Parsortix system. CTCs were
detected in 50% of breast cancer patients, 50% of NSCLC patients
and 36% of melanoma patients. CTC positivity rates were superior
when compared to previous studies into cancer brain metastases
which utilised other CTC enrichment technologies, including the
leading antibody-based system where positivity rates of 20-22% in
breast cancer and 12.5% in NSCLC have been reported.
Brain metastases are the most common type of brain tumour
accounting for 88% of all new cases. The incidence of cancer brain
metastases is increasing as new therapeutics, advanced imaging, and
improved screening have led to increased survival following a
primary diagnosis of cancer with approximately 200,000 new cases of
brain metastases being diagnosed in the United States each
year.
Brain metastases are a significant cause of morbidity and
mortality in patients. Prognosis is poor with life expectancy
usually less than a year and a five-year survival rate of only
2.4%. In addition, brain metastases are associated with loss of
cognitive and sensory function and, in many patients, lead to a
significant reduction in quality of life.
This study further confirms the utility of the Parsortix system
for the isolation and characterisation of CTCs in brain metastases
and that a Parsortix-based blood test may provide additional
medical information to inform treatment decisions that could
otherwise only be obtained by a highly invasive tissue biopsy of
the patient's brain.
The research has been published as a peer-reviewed publication
in the International Journal of Molecular Sciences and may be
accessed via https://angleplc.com/library/publications/ .
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This is important new work by the world-leading
Hamburg-Eppendorf cancer centre. Prof. Wikman and her team have
demonstrated the utility of the Parsortix(R) system in isolating
CTCs from cancer brain metastases and demonstrated superior CTC
positivity rates than those seen in studies using other enrichment
technologies. Cancer brain metastases cannot be accessed for tissue
biopsy without highly invasive procedures and a liquid biopsy
alternative would be of great benefit to patients to monitor and
optimise treatment."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and is currently in
the process of a 200-patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (AUC-ROC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
46 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of the Parsortix system in cancer drug trials and, once the
laboratories are accredited, and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAXVLFBFDLFBBZ
(END) Dow Jones Newswires
July 09, 2021 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2023 to Mar 2024